Street Calls of the Week
NEW YORK - Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company with a market capitalization of $5 million, announced Thursday that a patient with urothelial cancer and liver metastases achieved a partial response during Decoy20 monotherapy in its ongoing INDP-D101 clinical trial. According to InvestingPro data, the company’s shares have declined over 86% in the past year.
According to the company, the patient, who had previously received anti-PD-1 therapy, showed a clear reduction in liver metastases. However, disease progression was observed at the next scheduled imaging, and the patient discontinued from the study.
"The investigator believes the therapy provided clinical benefit for the patient over that 4-month period," said Dr. Roger Waltzman, Chief Medical Officer of Indaptus.
The company has completed the monotherapy portion of its trial and has initiated combination therapy with tislelizumab, an anti-PD-1 monoclonal antibody from BeOne. Seven patients have been dosed in the initial safety cohort of the combination therapy. Of the first three evaluable patients, one showed stable disease at first assessment while two experienced disease progression. InvestingPro analysis indicates the company’s financial health score is weak, with analysts not anticipating profitability this year.
The clinical-stage biotechnology company also reported raising approximately $5.7 million in gross proceeds through the sale of convertible promissory notes and accompanying warrants. In July 2025, these notes were converted into common stock and pre-funded warrants. The company’s current ratio of 0.75 suggests short-term obligations exceed liquid assets, highlighting the importance of this fundraising. Get deeper insights into Indaptus’s financial health metrics with InvestingPro, which offers 12 additional investment tips for this stock.
Indaptus’ Decoy platform is based on attenuated and killed, non-pathogenic bacteria designed to activate immune responses against tumors. The company expects to share initial combination trial data later this year, according to the press release statement.
In other recent news, Indaptus Therapeutics has made significant financial and strategic moves. The company announced it has raised a total of $5.7 million through the sale of convertible promissory notes and accompanying warrants, with the notes carrying a 6% annual interest rate and maturing on July 28, 2026. Additionally, Indaptus Therapeutics’ Board of Directors approved a one-for-twenty-eight reverse stock split, which will take effect after market close, and shares will begin trading on a split-adjusted basis. In a separate announcement, the company confirmed it has regained compliance with Nasdaq’s minimum bid price requirement, having maintained a closing bid price of at least $1.00 per share for 10 consecutive business days. This compliance follows a previous notification of non-compliance received in January. The company continues to focus on its strategic financial restructuring, as evidenced by its recent capital-raising activities and stock split approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.